Mach7 Technologies Limited Overview
Mach7 Technologies is a small-cap, ASX-listed healthcare software company focused on enterprise imaging. Its products manage, orchestrate and display diagnostic images across health systems. The platform has three layers. The first is a Vendor Neutral Archive (VNA) that consolidates DICOM and non-DICOM imaging without proprietary lock-in. The second is the eUnity zero-footprint enterprise diagnostic viewer, acquired with Client Outlook in 2020. The third is a newer suite of "Flamingo" orchestration modules for routing, normalisation, anonymisation and lifecycle management. After a reset year in FY26 under CEO Teri Thomas, recurring revenue reached 84% of a A$27.9M revenue base, while operating costs fell 16%. Management's ambition is to become the "default orchestration platform" in its category, which it also calls the "imaging EMR." The thesis rests on a simple idea: as AI becomes a heavy consumer of imaging data, the vendor-neutral data layer underneath becomes more valuable. Mach7 competes against far larger PACS and enterprise-imaging vendors. It is debt-free but loss-making on a statutory basis.
Company's own description (FY26 Result, 28 Aug 2026)
Mach7 describes itself as a healthcare software company that provides enterprise imaging solutions for modern, AI-enabled healthcare environments. In its own words, the platform comprises a VNA, the eUnity Enterprise Diagnostic Viewer and an expanding set of Flamingo modules. Together these help healthcare organisations build a unified, longitudinal patient record that integrates diagnostic imaging with broader clinical data. The company says it is increasingly aligned with cloud ecosystems such as Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI). Its customers include integrated delivery networks (IDNs), national health systems and specialist imaging providers.
Independent characterisation
Mach7 sits in the imaging IT infrastructure layer of the healthcare software value chain. Below it are imaging modalities (CT, MRI, X-ray, ultrasound, mammography, digital pathology scanners) and departmental PACS. Above it are electronic health records (EHRs, notably Epic and Oracle Health/Cerner) and AI applications. Mach7's job is to make images held in many departmental silos available enterprise-wide, under the customer's control, in standard formats.
The company frames this shift as moving "from storage to orchestration." Its argument is that storing images is becoming a commodity, as cloud object storage gets cheaper and hyperscaler imaging services such as AWS HealthImaging emerge. Normalising, routing and governing imaging data, by contrast, keeps its value. Mach7 explicitly says it is not a diagnostic-AI company. Instead, it presents itself as the infrastructure that delivers AI results to users and makes AI training easier (FY26 Result Presentation).
Business model and revenue model
| Revenue mix indicator | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Recurring revenue % of total | 49 | 54 | 72 | 75 | 84 |
| Recurring revenue coverage of OPEX % | — | — | 72 | 80 | 88 |
Mach7 earns revenue from four streams (FY21–FY26 results):
-
Subscription fees. Term subscriptions, including SaaS and cloud-hosted deployments, recognised over time from First Productive Use (FPU).
-
Maintenance and support fees. Annual support on perpetual or term licences. Together with subscription, this forms "recurring revenue."
-
Capital software licence fees. One-off perpetual or term licence sales, recognised on delivery. These are lumpy and milestone-driven.
-
Professional services. Implementation, data migration, integration and training.
Sources: FY23 Result (FY22–FY23 recurring share); FY25 Result (FY24–FY25 share and OPEX coverage); FY26 Result (FY26).
The model shift is deliberate. Since FY24, Mach7 has steered new North American sales toward multi-year subscriptions rather than capital licences. This lowers near-term recognised revenue but raises predictability. The FY24 transition caused revenue to dip slightly, even though FY24 sales orders were a record A$61.3M TCV (FY24 AGM address, Nov 2024). In FY26, ARR-type sales made up 86% of total sales orders (Appendix 4E, FY26). In Q4 FY26, a long-standing academic customer converted from the historical capital licence model to a five-year, A$2.8M TCV subscription (Q4 FY26 Business Update).
Gross margin is very high, as is typical for software. It was 96% in FY22, 97% in FY23 (FY23 Result) and 93% in FY26 (FY26 Result Presentation). The main cost lines are staff (A$22.6M of A$29.8M operating payments in FY26 per the Appendix 4C), administration (A$4.8M), product/operating costs (A$1.2M) and marketing (A$1.0M).
Customer types and end-markets
Integrated delivery networks and hospital systems (US): Examples include Adventist Health, Sentara Healthcare, Penn State Health, UnityPoint Health, Advocate Aurora Health (historic) and a leading academic medical centre (unnamed). Trinity Health was a customer until its non-renewal in FY26.
National and government health systems: Examples are the Hospital Authority Hong Kong (HAHK) and the US Veterans Health Administration (VHA). Mach7 was a subcontractor on the VHA NextGen PACS programme, which ceased in FY26.
Teleradiology and specialist imaging groups: Examples include AMRADNET (American Radiologist Network Inc.), DocPanel and Diagnostic Imaging Associates (DIA).
Regional and Middle East health systems: These are served through channel partner Allarch.
End-markets: radiology (core), cardiology, oncology, teleradiology, and newly digital pathology. eUnity digital pathology capabilities were showcased at SIIM26 in June 2026, and the Q3 FY26 Presentation cited early traction in this area. Regions served are North America (primary), Asia-Pacific, the Middle East (GCC) and, to a lesser degree, Europe. Mach7 is pursuing MDR compliance and the CE Mark (H1 FY26 Result).
Strategy
Stated strategy themes (FY26 Result and Presentation, 28 Aug 2026; H1 FY26 call)
Vision: to be "the global imaging EMR." Imaging is presented as the last major unstructured, fragmented component of the patient record (H1 FY26 and Q2 FY26 calls).
Theme: "From Archive to Architecture." The aim is to move value capture from storage, which is commoditising, to orchestration (normalising, routing, governing).
Ambition: become the default orchestration platform in its category. The intended routes are broader reach through partners, expansion into more imaging use cases ("-ologies," pathology), greater pricing power, and recognition as the safest long-term choice for customers.
Three-phase horizon: 1. Stabilise. Largely complete: cost base reset, recurring engine protected, leadership rebuilt.
-
Prove the growth engine. FY27: show operating leverage, with revenue growing faster than OPEX.
-
Compound and lead. The longer-term ambition.
FY27 KPIs set by management: - ARR growth
-
New customer wins
-
Flamingo module adoption
-
OPEX discipline with a drive to profitability
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| CEO-led strategic review and reset | Jul 2025 onward | Buy-back paused, cost restructure, new leadership, single product roadmap | Completed in FY26 (A$1.9M restructuring cost) |
| Customer engagement model ("Flight Crew") | FY25–FY26 | Designated cross-functional teams per customer, executive sponsorship, enterprise business reviews | Operational. KLAS eUnity score 86.6 |
| Flamingo platform launch | 21 Nov 2025 (RSNA) | Modular orchestration platform | First production go-live at UnityPoint (Q4 FY26); new modules due at RSNA 2026 |
| Next-generation containerised architecture | FY26 | Enables a land-and-expand modular sales motion | In development |
| AI-assisted software development | FY26 | Used to accelerate delivery and improve quality (Q4 FY26 update) | Ongoing |
| Cloud alignment (AWS, OCI) | Feb 2025 onward | eUnity on AWS HealthImaging; OCI alignment | Ongoing |
| Partner ecosystem build-out | FY26 | 10 partners activated across four categories: strategic alliances, regional resellers, clinical workflow integrators and international partners (Q3 FY26). Includes Dell, AWS, Oracle, Allarch and Howard Medical | Expanding |
| Epic interoperability | Q4 FY26 | eUnity listed in Epic Connection Hub | Achieved |
| Digital pathology / "-ologies" expansion | H2 FY26 | eUnity digital pathology capabilities (SIIM26) | Early traction cited (Q3 FY26) |
| Regulatory expansion | FY26 | MDR compliance and CE Mark pathway | In progress (H1 FY26) |
| Subscription conversion | FY24 onward | Capital-to-subscription transition in North America | Recurring share at 84% (FY26) |
| Capital management | Jan 2025 to Mar 2026 | On-market buy-back (6.3M shares for A$2.2M in FY25). Paused Aug 2025; completion announced Mar 2026 | Closed |
ESG and sustainability commitments
No quantified emissions targets or sustainability-linked initiatives were identified in the documents reviewed.
Guidance and medium-term targets
| Item | Guidance / target | Outcome |
|---|---|---|
| FY26 revenue | About 15% below FY25 (Q3 FY26, reaffirmed Q4 FY26) | −17% to A$27.9M, described as "in line with" guidance |
| FY26 OPEX | About 10% below FY25 | −16% to A$26.7M, beating guidance |
| FY27 | No quantitative revenue or EBITDA guidance identified. Qualitative: operating leverage, ARR growth, new logos, module adoption | — |
| Long-standing target | Recurring revenue to cover 100% of OPEX | 88% in FY26 (FY24: 72%; FY25: 80%) |
| FY25 guidance (historic) | Revenue and CARR growth of 15–25%; OPEX growth below revenue growth | Revenue +16% (met); CARR below the original range (revised to A$30–31M in Jul 2025) |
Products & Services
Because Mach7 is a single segment, products are organised below by platform layer.
Layer 1 — Enterprise Data Management (VNA)
| Attribute | Detail |
|---|---|
| Product | Mach7 Vendor Neutral Archive (VNA), part of the Mach7 Enterprise Imaging Platform, historically branded Enterprise Data Management |
| Description | Consolidates and stores imaging data natively or in DICOM, on-premise, in the cloud or hybrid. No proprietary wrapping and no exit fees (FY26 Presentation) |
| Key capabilities | DICOM and non-DICOM ("-ology") ingestion; tag morphing and normalisation; lifecycle management; data migration from legacy PACS; multi-site federation; EHR integration |
| Core technology | Mach7 Management Studio, covered by a US patent awarded for managing enterprise imaging data across distributed health systems (company announcement) |
| Target customer | IDNs, academic medical centres, national health systems |
| Pricing model | Historically capital licence plus annual maintenance; now predominantly multi-year subscription |
| Customer satisfaction | KLAS VNA score improved from 68.7 to 73.6 across measurement periods (FY26 Presentation) |
| Latest version | n.d. A "next-generation containerised architecture" is in development to enable land-and-expand selling |
Layer 2 — Enterprise Viewing (eUnity)
| Attribute | Detail |
|---|---|
| Product | eUnity Enterprise Diagnostic Viewer, acquired with Client Outlook Inc. in July 2020 |
| Description | Zero-footprint (browser-based, no client install) diagnostic and clinical image viewer with full image fidelity. Designed as both a viewer and an integration platform |
| Key capabilities | Diagnostic reading; clinical and referring-physician viewing; mobile access (patent-awarded mobile technology); EHR image-enablement (Epic); teleradiology workflows; digital pathology viewing (showcased at SIIM26, Jun 2026) |
| Cloud variants | eUnity on AWS HealthImaging (launched 27 Feb 2025); OCI alignment |
| Ecosystem milestone | Listed in Epic Connection Hub (Q4 FY26), making eUnity publicly discoverable by Epic customers for image-enabling EHR workflows |
| Target customer | IDNs, teleradiology groups (e.g. AMRADNET, DocPanel), imaging centres, Epic-based health systems |
| Pricing model | Subscription (for example, AMRADNET 5-yr A$1.7M TCV) or licence plus support |
| Customer satisfaction | KLAS score of 86.6, above segment average; "would buy again" above 90 vs a KLAS market average of 83.1 (FY26 Presentation) |
| Deployment speed | AMRADNET achieved first productive use in 45 days |
Layer 3 — Orchestration (Flamingo modules)
| Attribute | Detail |
|---|---|
| Product | Flamingo modular orchestration platform, launched at RSNA 2025 (21 Nov 2025) under the "From Archive to Architecture" theme |
| Description | Rules-based routing, normalisation, anonymisation and lifecycle management of imaging data across systems. Positioned as the layer that must orchestrate imaging data before AI can reliably consume it |
| First deployment | UnityPoint Health, the first production deployment (Q4 FY26). Went live and generated revenue in under half the typical implementation time |
| Roadmap | New Flamingo modules scheduled to launch at RSNA 2026 with named early-adopter customers (FY26 Presentation) |
| Pricing model | Modular subscription (per-module adoption is a stated FY27 KPI) |
| Target customer | Existing VNA customers (expansion) and new logos seeking AI-ready imaging infrastructure |
Workflow and departmental applications
| Product | Description | Status |
|---|---|---|
| Universal Worklist | Enterprise reading worklist used in teleradiology PACS workflows (historic Client Outlook partnership, 2020) | Active (latest version n.d.) |
| Mach7 PACS / Diagnostic Workflow Applications | Mach7 VNA plus eUnity plus worklist, configured as a PACS replacement (e.g. Adventist Health, 22 hospitals; Sentara PACS "powered by Mach7") | Active |
| Analytic Studio | Analytics module previewed at RSNA 2019 | Current status n.d. |
| Tele-imaging platform | Roadmap item disclosed in the Q1 FY26 Presentation (Oct 2025) | In development |
Services
| Service | Description |
|---|---|
| Professional services | Implementation, data migration (e.g. the historic Sentara migration project), integration, training. FY26 revenue about A$3.0M (derived) |
| Support and maintenance | Annual support contracts. Included in recurring revenue |
| Customer success / "Flight Crew" | Designated cross-functional teams with executive sponsorship and enterprise business reviews (FY26) |
Discontinued or legacy
3D Medical's medical 3D printing distribution business was part of the 2016 merged entity. It is not referenced in recent disclosures, and its current status is n.d.
Financial Narrative
Income statement
Sources and notes: - Revenue, NPAT and NPATA are from the FY22, FY23, FY25 and FY26 Results. FY24 is from the FY24 AGM address and FY25 Result.
-
Gross profit: FY22 and FY23 from the FY23 Result. FY26 is derived from the 93% gross margin in the FY26 Presentation.
-
FY24 OPEX is derived from FY25 OPEX growth of 9%. FY25 OPEX of A$31.8M is from the FY26 Presentation.
-
Reported EBITDA: FY23 from the Wilsons model (2 May 2025); FY24 and FY25 from the FY25 Result.
-
Adjusted EBITDA: FY23 and FY24 from the FY24 AGM address, FY25 and FY26 from the respective Results.
-
Pre-tax income: FY22–FY26 statutory pre-tax figures were n.d. in the documents reviewed. The NPAT figures include material income-tax benefits; for example, FY23 NPAT benefited from a A$3.4M increase in tax benefits (FY23 Result), and the FY26 loss widened partly due to lower tax benefits (Appendix 4E).
EPS from Simply Wall St summary of FY24 results (FY24 −3.3c; FY23 −0.4c). Diluted EPS n.d. Mach7 has never paid a dividend. NTA per share from the Appendix 4E. Implied FY26 basic EPS is about −3.8c (derived: A$8.9M ÷ ≈234M shares) and is not company-reported.
Margins other than gross margin are derived from the table above.
Revenue CAGR: FY22–FY26 is +0.7% p.a. FY21–FY26 is +8.0% p.a. (from FY21 revenue of A$19.0M, FY21 Result). Both are derived.
Commentary. The five-year revenue line is essentially flat, which captures the core investment debate. Between FY22 and FY23, revenue grew on large capital licence deals: the Adventist PACS rollout, HAHK and renewals. In FY24, management deliberately pivoted new sales to subscription, so revenue slipped about 3% even as sales orders hit a record A$61.3M TCV and ARR rose about 30%. FY25 was the payoff year. Recurring revenue rose 20% as subscription contracts reached FPU, and revenue grew 16% to A$33.8M.
FY26 reversed that gain. Two material recurring contracts were lost: the Trinity Health non-renewal and the VHA programme cancellation. Capital licence revenue collapsed 70% to A$1.5M, reflecting conversions to subscription, delayed capital deals in the Middle East and Asia, and lower expansion volumes. Professional services also softened. The underlying "quality" metrics improved: recurring revenue rose to 84% of revenue and covered 88% of OPEX. But the absolute recurring base fell 8%.
The statutory loss widened to A$8.9M. Three things drove this: amortisation of acquired intangibles (the gap between NPAT and NPATA was about A$6.0M in FY26), A$1.9M of restructuring costs, and lower tax benefits.
The company describes H2 FY26 as an inflection. H2 revenue of A$14.3M exceeded H1's A$13.7M despite currency headwinds, adjusted EBITDA improved from −A$2.3M in H1 to about +A$1.4M implied in H2 (derived from the full-year −A$0.9M), and Q2–Q4 operating cash flow was positive.
Balance sheet
Sources and notes: - Cash: FY23–FY24 from the Wilsons model (2 May 2025); FY25 and FY26 from the FY26 Result.
-
Mach7 has carried no borrowings in any period reviewed. The Q4 FY26 Appendix 4C reports nil loan facilities.
-
Total assets and equity for FY25 are from the FY25 Annual Report (filed 28 Oct 2025) as compiled by FinancialFilings.
-
Net current assets of A$20.06M at 30 Jun 2023 are from the H1 FY24 Half Year Report.
-
Goodwill and intangibles are n.d. They are material, given the ≈A$40.9M Client Outlook acquisition and ongoing amortisation (≈A$6.0M p.a. gap between NPAT and NPATA in FY26).
-
FY26 statutory balance sheet totals were n.d. at the time of writing. The decline in NTA/share from 9.8c to 8.0c implies tangible equity of roughly A$19–23M (derived).
Commentary. The balance sheet is Mach7's defining defensive asset. Cash of A$19.9M with no debt equals about 70% of FY26 revenue. On the 6 Jul 2026 market capitalisation (A$69M) it was roughly 29% of market value; on the early-October OTC-implied value (~A$50M) it was about 40%. Cash fell A$3.2M in FY26. The drivers were an operating outflow of A$1.4M (mostly Q1, which included restructuring payments), A$0.9M of capitalised development and PP&E, and a A$0.8M FX translation loss on USD cash (Appendix 4C FY26). Deferred revenue, a key working-capital item for an upfront-billing software company, was n.d. for FY26.
Cash flow
Sources and notes: - Cash receipts: FY22 Result (A$28.2M); FY26 Appendix 4C (A$27.96M).
-
Operating cash flow: FY24 from the Q4 FY24 call (A$3.2M); FY25 from the FY25 Result (A$0.9M; A$0.87M per the Annual Report); FY26 from the Appendix 4C (−A$1.438M).
-
FY23 operating cash flow was positive per company commentary, but the amount was n.d.
-
Capitalised development: FY24 and FY25 from the FY25 Result; FY26 from the Appendix 4C (A$0.847M).
FY24–FY25 free cash flow is derived and excludes PP&E: - Buy-backs: 6.3M shares for A$2.2M in FY25 (FY25 Result). The FY26 YTD financing cash flow was a net +A$12k; buy-back activity was paused from 27 Aug 2025 and completion was announced in Mar 2026.
Q3 and Q4 are from the Q3 and Q4 FY26 updates. Q4 is A$1.063M. Q1 and Q2 are derived from the FY26 total of −A$1.438M, with Q2 described as positive. The Q1/Q2 split is approximate: Q2 was reported positive, so Q1 was roughly −A$3.3M to −A$3.6M. Treat both as indicative.
Ratios
FY25 ratios are derived from FY25 Annual Report totals (assets A$64.2M, equity A$45.6M). Net-debt and interest metrics are not meaningful (n/m) because the company has no debt and net cash. Other ratios await the FY26 Annual Report.
Recurring-revenue KPIs
Sources and notes: - ARR: FY22 Result (A$14.4M), FY23 Result (A$17.0M), FY24 AGM address (A$22.0M), FY26 Presentation (A$23.5M for both FY25 and FY26; FY26 is +7.6% in constant currency).
-
Note the discrepancy: H1 FY25 ARR was reported at A$25.1M and Mar-25 at A$24.4M. The A$23.5M FY25 comparative in the FY26 Presentation appears to reflect the FY25 closing figure, possibly at different FX.
-
CARR: FY23 from the Q4 FY23 update; FY24 from the Q4 FY24 call (A$27.9M).
-
FY25 CARR is shown as derived (A$25.5M ÷ (1 − 8.9%) ≈ A$28.0M, per the Q4 FY26 update). This conflicts with the Jul 2025 guidance of "A$30–31M." The difference likely reflects FX restatement or customer losses after guidance; both figures are noted.
-
Sales orders: FY22 derived from FY23 A$40.3M being up 21%; FY24 from the FY24 AGM address.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue type (AUD Mn)
| Revenue type (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Recurring revenue (subscription + maintenance & support) | 13.4 | 16.3 | 21.1 | 25.3 | 23.4 |
Capital software licence revenue | 10.8 | 11.0 | — | 5.0 | 1.5 |
Professional services and other (derived) | 2.9 | 2.8 | — | 3.5 | 3.0 |
Non-recurring revenue total (derived) | 13.7 | 13.8 | 8.0 | 8.5 | 4.5 |
Total revenue | 27.1 | 30.1 | 29.1 | 33.8 | 27.9 |
Growth and contribution (%)
| Growth and contribution (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Recurring revenue YoY growth | 22 | 29 | 20 | -8 |
Total revenue YoY growth | 11 | -3 | 16 | -17 |
Capital licence YoY growth | 2 | — | — | -70 |
Recurring share of total revenue | 54 | 72 | 75 | 84 |
Product share of product revenue (%)
| Product share of product revenue (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
VNA / Enterprise Data Management | 60 | 60 | 54 |
eUnity Enterprise Viewer | 40 | 40 | 46 |
Income Statement
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 27.1 | 30.1 | 29.1 | 33.8 | 27.9 |
Gross profit | 26.1 | 29.1 | — | — | 25.9 |
Operating expenses (OPEX) | — | — | 29.2 | 31.8 | 26.7 |
EBITDA (reported, normalised) | — | 1.7 | -3.3 | -1.5 | — |
Adjusted EBITDA (excl. unrealised FX and SBP) | — | 2.5 | -2.0 | -0.3 | -0.9 |
NPATA | 4.4 | 7.2 | -1.2 | 0.4 | -2.9 |
Net profit after tax (NPAT) | -4.2 | -1.0 | -8.0 | -6.2 | -8.9 |
Per-share metrics (A$ cents)
| Per-share metrics (A$ cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS basic | — | -0.4 | -3.3 | — | — |
Dividends per share | 0 | 0 | 0 | 0 | 0 |
NTA per share | — | — | — | 9.8 | 8.0 |
Margins (%)
| Margins (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 96 | 97 | — | — | 93 |
Adjusted EBITDA margin | — | 8.3 | -6.9 | -0.9 | -3.2 |
NPATA margin | 16.2 | 23.9 | -4.1 | 1.2 | -10.4 |
Net margin | -15.5 | -3.3 | -27.5 | -18.3 | -31.9 |
Balance Sheet
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents | — | 23.4 | 26.2 | 23.1 | 19.9 |
Total debt | 0 | 0 | 0 | 0 | 0 |
Net debt (negative = net cash) | — | -23.4 | -26.2 | -23.1 | -19.9 |
Total assets | — | — | — | 64.2 | — |
Total equity | — | — | — | 45.6 | — |
Net current assets (working capital) | — | 20.1 | — | — | — |
Cash Flow
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash receipts from customers | 28.2 | — | — | — | 28.0 |
Operating cash flow | — | — | 3.2 | 0.9 | -1.4 |
Capitalised development (intangibles capex) | — | — | 0.2 | 0.9 | 0.8 |
PP&E capex | — | — | — | — | 0.1 |
Free cash flow (OCF minus capex) | — | — | 3.0 | 0.0 | -2.4 |
Share buy-backs | 0 | 0 | 0 | 2.2 | 0.0 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Quarterly operating cash flow FY26 (AUD Mn)
| Quarterly operating cash flow FY26 (AUD Mn) | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|
Net cash from operating activities | -3.3 | 0.0 | 1.2 | 1.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE % (NPAT / closing equity) | — | — | -13.6 | — |
ROA % (NPAT / closing assets) | — | — | -9.7 | — |
ROIC | — | — | — | — |
Debt / equity (x) | 0 | 0 | 0 | 0 |
Net debt / EBITDA | n/m | n/m | n/m | n/m |
Interest coverage | n/m | n/m | n/m | n/m |
Asset turnover (x) | — | — | 0.53 | — |
Current ratio | — | — | — | — |
Cash conversion cycle | — | — | — | — |
Key Financials
| KPI (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ARR run rate at 30 June | 14.4 | 17.0 | 22.0 | 23.5 | 23.5 |
CARR at 30 June | — | 20.6 | 27.9 | 28.0 | 25.5 |
Sales orders TCV | 33.3 | 40.3 | 61.3 | — | — |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
North America | — | — | — |
Asia-Pacific | — | — | — |
Middle East | — | — | — |
Europe / Other | — | — | — |
Total | 29.1 | 33.8 | 27.9 |
Share Price & Returns
| Reference date | Share price (AUD) | Source |
|---|---|---|
Aug 2020 (post-Client Outlook) | 1.11 | ASX announcement price log |
Aug 2023 (FY23 result) | 0.78 | ASX announcement price log |
Aug 2024 (FY24 result) | 0.56 | ASX announcement price log |
Feb 2025 (H1 FY25) | 0.44 | ASX announcement price log |
Oct 2025 (Q1 FY26) | 0.295 | InvestSMART |
Nov 2025 (UnityPoint win) | 0.51 | ASX announcement price log |
Feb 2026 (H1 FY26) | 0.34–0.36 | ASX price log; Motley Fool |
4 May 2026 (CFO change) | 0.26 | RTTNews |
6 Jul 2026 | 0.295 | InvestSMART |
2 Oct 2026 (OTC TDMMF US$0.14) | ≈0.21 (implied, at about 0.66 AUDUSD) | Yahoo Finance (OTC); ASX quote to be verified |
Return metric (%) | 1-year | 3-year |
M7T total share price return (as of Feb 2026) | -12.2 | — |
Valuation Multiples
| Multiple | At A$0.295 (Jul 2026) | At ≈A$0.21 (implied, Oct 2026) |
|---|---|---|
Market capitalisation (AUD Mn) | 69 | ≈50 |
Enterprise value (AUD Mn, mcap minus A$19.9M cash) | ≈49 | ≈30 |
EV / FY26 sales (x) | ≈1.8 | ≈1.1 |
EV / FY26 recurring revenue (x) | ≈2.1 | ≈1.3 |
EV / ARR (x) | ≈2.1 | ≈1.3 |
P/e Details
| P/E | n/m (loss-making) | n/m |
|---|---|---|
EV/EBITDA | n/m (negative adj. EBITDA) | n/m |
P/B | n.d. (FY26 equity n.d.) | — |
Analyst Ratings & Targets
| Broker | Rating | Price target (AUD) | Date |
|---|---|---|---|
Morgans | Buy | 0.44 | Late Apr / May 2026 (after Q3 FY26) |
Wilsons | Overweight | 0.85 (revised from 1.15) | 30 Apr / 2 May 2025 (dated) |
TipRanks-recorded analyst | Hold | 0.50 | Around Aug 2025 |
Coverage breadth | About 8 analysts cover the stock; about 3 contribute estimates | — | Simply Wall St |
Capital Markets
| Item | Status |
|---|---|
Dividend history | Never paid a dividend; none recommended or declared for FY26 (Appendix 4E) |
Dividend policy | None. Capital retained for growth and selective investment |
Buy-back | On-market programme announced 30 Jan 2025, commenced 3 Mar 2025. 6.3M shares bought for A$2.2M in FY25; paused 27 Aug 2025; completion announced Mar 2026. No new authorisation identified |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Not applicable (no debt, no facilities) |
Analyst Conclusions
Management guidance
No quantitative FY27 guidance was identified. Management's stated FY27 priorities are positive customer outcomes, new customer wins, expanding revenue from the installed base, and visible operating leverage. The KPI scorecard comprises ARR growth, new logos, Flamingo module adoption and OPEX discipline. Capital allocation is to remain disciplined, investing selectively where returns are clear (FY26 Result).
Consensus expectations
Not publicly available in the sources reviewed. Simply Wall St (Dec 2025) cited forecast revenue growth of about 10.8% p.a. and continued losses over three years. That pre-dates the FY26 result and should be treated as stale.
Bull case
-
Operating leverage is already visible. OPEX fell to A$26.7M against an ARR run rate of A$23.5M growing 7.6% in constant currency. Recurring revenue already covers 88% of OPEX. Modest ARR growth (about A$3M) combined with flat costs would close the gap, and with 93% gross margins most incremental revenue drops to profit. H2 FY26 adjusted EBITDA was positive (derived) and operating cash flow was positive in three straight quarters.
-
Distribution step-change. Epic Connection Hub, Howard Medical (more than 3,700 hospitals), AWS, OCI, Dell and Allarch give a sub-scale vendor reach it could not fund alone. eUnity's 86.6 KLAS score and the 45-day AMRADNET go-live provide differentiated proof points to convert that reach.
-
Valuation floor and optionality. At an implied EV of about A$30–49M, the market pays only about 1.1–2.1x recurring revenue for a high-margin, debt-free software asset with A$19.9M cash. The CEO previously sold Volpara to a strategic acquirer. Larger imaging players seeking vendor-neutral orchestration could find Mach7 an inexpensive tuck-in.
Bear case
-
The base is shrinking, not compounding. Revenue is flat over five years (A$27.1M in FY22 vs A$27.9M in FY26). CARR fell 8.9% to A$25.5M, and backlog not yet live is only A$2.0M. Two contract losses in a single year show how fragile a small customer base is.
-
Execution and leadership risk. The company is on its third CFO in about a year (an interim CFO is in place), and seven senior leaders were appointed in 12 months. Flamingo has one production deployment. The reset narrative must now be proven with numbers. Repeated guidance shortfalls (FY25 CARR, FY26 revenue) have eroded credibility.
-
Structural squeeze. Hyperscalers commoditise storage while large vendors bundle imaging IT with modalities. Better-capitalised specialists (Sectra, Visage) win marquee replacements. With capitalised development of under A$1M a year, Mach7 risks being out-invested in the AI-orchestration layer it is targeting.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| ~Late Oct 2026 | FY26 Annual Report; Q1 FY27 Appendix 4C | Remuneration structure and KPIs; top-20 register; geographic revenue note; Q1 cash flow (seasonally weakest) |
| Late Nov / Dec 2026 | RSNA 2026 Flamingo module launch; 2026 AGM | Named early adopters; first module revenue; any board renewal |
| Q2 FY27 (Jan 2027) | Quarterly update | New logos; ARR above A$24M; CARR stabilisation |
| Feb 2027 | H1 FY27 result | Year-on-year revenue growth; positive adjusted EBITDA |
| Ongoing | Permanent CFO appointment | Leadership stability |
| Ongoing | Middle East capital deal conversion | Revenue upside, or further slippage |
| Ongoing | Further churn disclosures | Contract renewals in the installed base |
| Ongoing | Corporate activity | Any approach given the low EV and CEO track record |
Analyst verdict
Mach7 enters FY27 as a cleaner but smaller business. The FY26 reset did what resets should do. Cost fell 16%, recurring revenue rose to 84% of the mix and to 88% coverage of OPEX, operating cash flow turned positive for three quarters, and the balance sheet stayed debt-free with A$19.9M of cash. Product credibility also improved measurably. eUnity's KLAS score of 86.6 sits above the market, the VNA score is climbing, deployments are faster, and the Epic Connection Hub listing is real distribution leverage for a company of this size.
Against that, the hard numbers have gone backwards. Revenue fell 17%, CARR fell 9%, and the statutory loss widened to A$8.9M. Five years of revenue history show essentially no growth. The FY26 losses of Trinity Health and the VHA programme also exposed how much a handful of contracts drive outcomes. Leadership turnover at the CFO level is an unwelcome signal in the very year execution matters most.
The investment case is therefore a binary test of operating leverage. Management has set the right KPIs: ARR growth, new logos, Flamingo adoption and OPEX discipline. The arithmetic is favourable, because a few million dollars of net new ARR on a fixed cost base would make Mach7 sustainably profitable at the EBITDA line. The market, however, is pricing failure. At an implied enterprise value of roughly 1–2x recurring revenue, the shares embed little credit for the reset. That creates asymmetric upside if FY27 shows even modest ARR growth, and strategic optionality given the CEO's exit history.
Our assessment is speculative / high-risk, positive-skew. The balance sheet protects downside in the near term, but conviction requires evidence. The key tests are Flamingo module revenue after RSNA 2026, at least two new enterprise logos, and H1 FY27 revenue growth. Until those arrive, Mach7 remains a show-me turnaround rather than a proven compounder.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Board tenure | Background | Independence |
|---|---|---|---|---|
Robert (Rob) Bazzani | Non-Executive Chairman | Since Jan 2020 (Chair after the Chambers era; exact date n.d.) | More than 30 years in corporate finance and advisory. 21 years at KPMG, including membership of KPMG's National Executive Committee. NED of OFX Group (since Feb 2024) and Keypath Education International (since May 2021). Chair of Risk and Compliance Committee | Independent NED |
Teri Thomas | Managing Director & CEO | Since 1 Jul 2025 | Former CEO of Volpara Health Technologies (ASX: VHT), where she led a turnaround and sale to Lunit; later Chief Business Officer of Lunit | Executive |
Rebecca Thompson | Non-Executive Director; Chair, Audit & Risk Committee | Since Nov 2023 (advisor in the prior year) | Former Head of Investor Relations at CSR Limited (acquired by Saint-Gobain in 2024). BEc (University of Sydney), GradDip Applied Finance & Investment (FINSIA), MAICD | Independent NED |
Dr Eliot L. Siegel | Non-Executive Director | Tenure n.d. | Radiologist and imaging-informatics authority. The company website notes a board member of Carestream Health and numerous imaging advisory boards; attribution to Dr Siegel is inferred from the website ordering | Independent NED (assessed) |
Executive Leadership Team
| Name | Title | Appointed | Notes |
|---|---|---|---|
Teri Thomas | MD & CEO | 1 Jul 2025 | See above |
Shawni Hadfield | Interim CFO | 4 May 2026 | Previously VP Commercial Excellence. Prior CFO experience and SaaS finance expertise (CFO Transition, 4 May 2026) |
Brian Wehrle | Chief Technology Officer | 6 May 2026 | Leads unified product, support and engineering (company press release; FY26 Presentation) |
Todd Stallard | EVP Sales & Marketing | FY26 (date n.d.) | Presented at the Q3 FY26 webinar |
Paul Jensen | Chief Innovation Officer | Jul 2025 | First CIO role (Q4 FY25 Presentation). Current status n.d. |
David Madaffri | Chief Operating Officer | — | — |
Françoise Debelak Dixon | Head of Investor Relations | — | IR contact on all FY26 releases |
Naomi Lawrie | Company Secretary | 24 Jun 2025 | Corporate lawyer (Vistra Australia) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Apr 2025 (effective 30 Jun / 1 Jul 2025) | Mike Lampron (CEO since 2019) steps down; Teri Thomas appointed | Board sought turnaround and commercial-growth experience. Lampron had stabilised the business and delivered cash-flow positivity but not operating leverage |
Jul 2025 | Paul Jensen appointed Chief Innovation Officer | Innovation and product focus |
Oct 2025 | Daniel Lee appointed CFO | Replaced the prior CFO (name n.d.); CEO noted more than 500 applicants |
4 May 2026 | Daniel Lee resigns (family priorities); Shawni Hadfield becomes Interim CFO | Second CFO change in about seven months, a governance monitorable |
6 May 2026 | Brian Wehrle appointed CTO | Consolidation of engineering and product |
Directors' Remuneration
| Item | Amount | Source |
|---|---|---|
Executive Director (CEO) salary and superannuation, Q4 FY26 | A$144,314 for the quarter (≈A$577k annualised, derived) | Q4 FY26 Appendix 4C, section 6 |
Non-executive directors' fees and superannuation, Q4 FY26 | A$77,492 for the quarter (≈A$310k p.a. aggregate, derived) | Q4 FY26 Appendix 4C |
CEO short-term incentive (STI), long-term incentive (LTI) and equity grants | n.d. pending FY26 Annual Report | — |
Major Shareholders
| Holder | Stake | Notes / source |
|---|---|---|
Microequities Asset Management | Substantial holder; exact % n.d. | Bought about 2.38M shares (Jul 2025) and about 3.23M shares (Nov 2025) per substantial-holder notices compiled by Simply Wall St |
Australian Ethical Investment | Substantial holder; exact % n.d. | Bought about 2.57M shares (Oct 2025) |
Top 22 shareholders combined | About 50.5% | Simply Wall St ownership summary |
Rob Bazzani (Chair) | 427,869 shares (indirect) plus 100,000 options | Market Index, as of 30 Mar 2026. Repeated on-market buying in Nov 2025 and Mar 2026 |
Eliot Siegel (NED) | Bought 112,012 shares (Dec 2024) | Total holding n.d. |
Ravi Krishnan (founder) | Historically a significant holder; current % n.d. | — |
Competitive Landscape
Key Competitors
| Competitor | Relevant products | Overlap with Mach7 | Positioning vs Mach7 |
|---|---|---|---|
Hyland Software (private) | Acuo VNA, NilRead viewer, Enterprise Imaging suite | VNA and viewer | Long-standing VNA leader with a large content-services installed base |
GE HealthCare (NASDAQ: GEHC) | Centricity / True PACS, Enterprise Imaging, VNA | PACS, VNA, viewer | Scale player that bundles imaging IT with modalities |
Philips (AMS: PHIA) | Vue PACS, Image Management, IntelliSpace | PACS, VNA, viewer | Scale player; cloud PACS push |
Sectra AB (STO: SECT B) | Sectra One Cloud, PACS/VNA, digital pathology | Enterprise imaging, pathology | Strong KLAS performer; consistent winner of US IDN replacements |
Pro Medicus / Visage Imaging (ASX: PME) | Visage 7 Enterprise Imaging viewer and Open Archive | Viewer, archive | Market-leading cloud-native viewer in US academic medicine; Mach7's most-cited ASX comparable |
Fujifilm Healthcare | Synapse PACS, Synapse VNA | PACS, VNA | Bundled modality and IT vendor |
Agfa HealthCare (EBR: AGFB) | Enterprise Imaging Platform | Enterprise imaging | Strong in Europe; restructuring |
Intelerad Medical Systems (private) | InteleViewer, PowerServer, Nucleus | PACS, viewer, VNA | Acquisitive mid-market player |
Merative (formerly IBM Watson Health imaging) | Merge PACS, iConnect VNA | VNA, PACS | Legacy installed base |
Change Healthcare / Optum (UnitedHealth) | Enterprise imaging (legacy McKesson) | VNA, PACS | Legacy installed base |
Hyperscaler services (AWS HealthImaging, Google Cloud Healthcare API, Microsoft Azure Health Data Services) | Cloud imaging storage and APIs | Storage layer | Commoditising storage. Both a partner (AWS) and a potential disintermediator |
Peer Comparison FY2026
| Metric | Mach7 (FY26, A$) | Pro Medicus (FY25, A$) | Sectra (latest FY) | GE HealthCare (imaging IT, FY25) |
|---|---|---|---|---|
Revenue | 27.9M | — | — | Imaging IT not separately disclosed |
Revenue growth | -17% | — | — | — |
Gross margin | 93% | — | — | — |
EBITDA / EBIT margin | -3.2% (adj. EBITDA) | — | — | — |
Capitalised R&D intensity (% of revenue) | 3.0% | — | — | — |
Net cash | 19.9M | — | — | — |
Recent Developments
--



